1. Pink Sheet
  2. >>Geography
  3. >>Latin America

Mexico Launches ‘Regulatory Certainty Strategy’ For Biosimilars

 
• By Francesca Bruce

Mexico is to establish a new regulatory framework that is in line with international standards to encourage domestic production of biosimilar medicines. 

Mexico Meds
Mexico to improve access to medicines with biosimilar regulatory strategy • Source: Shutterstock

Mexico’s regulator, Cofepris, wants to drive local production and development of biosimilar medicines to increase access through a new regulatory and operational framework for these products. The plans include the creation of several new bodies, including a new Council for National Pharmaceutical Development.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Latin America

Brazilian Drug Price Increase Rates Hit Eight-Year Low

 
• By Francesca Bruce

CMED, which sets medicine prices in Brazil, has published the maximum price adjustment index for 2025.

Brazil Catches Up With International Standards on Viral Safety Evaluations For Biotech Products

 
• By Francesca Bruce

The Brazilian medicines regulator will also offer more clarity on the requirements for radiopharmaceuticals that are exempt from registration.

Brazil Consults On How To Price Advanced Therapies

 
• By Francesca Bruce

Brazil’s drug regulator ANVISA has also published its first post-marketing authorization monitoring reports on advanced therapies Yescarta, Zolgenma, Kymriah, Carvykti and Luxturna.

England’s NICE Leads Global Effort On Surrogate Endpoints For Cost-Effectiveness

 
• By Eliza Slawther

Health technology assessment bodies in England, the US, Canada, Australia, the Netherlands and Colombia have joined forces to produce guidance for drug developers on using surrogate endpoints for cost-effectiveness analyses.

More from Geography